Literature DB >> 2744072

Determination of dextromethorphan metabolizer phenotype in healthy volunteers.

M Hildebrand1, W Seifert, A Reichenberger.   

Abstract

The dextromethorphan metabolizer phenotype in 450 healthy volunteers (299 men, 151 women) was determined after oral administration of a 15 mg dose. In 8 h-postdose urine samples the ratio of dextrorphan (DOP) to dextromethorphan (DMP) was measured by HPLC. Urinary excretion of DMP and DOP within 8 h after the dose varied greatly between individuals, ranging from 0-11% and 0.04-100% of dose, respectively. In 143 test subjects the fraction of the dose of DMP in urine was below the detection limit. In the remaining 307 volunteers the metabolic ratio (MR) of DOP to DMP varied from 0.07 to 2906. In 404 test subjects the MR was greater than 10 and they were classified as extensive metabolizers (90% of the entire group). Of the entire group 5% had MRs of 1-10 and less than 1, respectively. Depending on the limit for classification of poor metabolizers, their frequency was 5-10% in the Caucasian population studied. The present data are in agreement with previous findings that the oxidative metabolic polymorphisms of debrisoquin and DMP co-segregate; the frequency of the PM phenotype of dextromethorphan in Caucasian populations varies between 5 and 10%.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2744072     DOI: 10.1007/bf00558166

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  [Polymorphisms and deficient drug metabolism as triggers of toxic reactions (author's transl)].

Authors:  H J Dengler; M Eichelbaum
Journal:  Arzneimittelforschung       Date:  1977

2.  Human pharmacogenetics: Introduction.

Authors:  R M Weinshilboum
Journal:  Fed Proc       Date:  1984-05-15

3.  Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation.

Authors:  M B Penno; E S Vesell
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

4.  Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.

Authors:  L Bertilsson; H J Dengler; M Eichelbaum; H U Schulz
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

5.  Influence of genetic polymorphism on the metabolism and disposition of encainide in man.

Authors:  T Wang; D M Roden; H T Wolfenden; R L Woosley; A J Wood; G R Wilkinson
Journal:  J Pharmacol Exp Ther       Date:  1984-03       Impact factor: 4.030

6.  Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

Authors:  B Schmid; J Bircher; R Preisig; A Küpfer
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

7.  Influence of the defective metabolism of sparteine on its pharmacokinetics.

Authors:  M Eichelbaum; N Spannbrucker; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

8.  Studies on the metabolism of perhexiline in man.

Authors:  R G Cooper; D A Evans; A H Price
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 9.  Genetic variation in the human hepatic cytochrome P-450 system.

Authors:  W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more
  11 in total

1.  Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α.

Authors:  Mario Furlanut; Giorgio Soardo; Debora Donnini; Leonardo Sechi; Loretta Franceschi
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

3.  Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation.

Authors:  N D Eddington; P Marroum; R Uppoor; A Hussain; L Augsburger
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

4.  Examining the Use of a Mechanistic Model to Generate an In Vivo/In Vitro Correlation: Journey Through a Thought Process.

Authors:  Bipin Mistry; Nikunjkumar Patel; Masoud Jamei; Amin Rostami-Hodjegan; Marilyn N Martinez
Journal:  AAPS J       Date:  2016-06-16       Impact factor: 4.009

5.  Influence of hydroxychloroquine on the bioavailability of oral metoprolol.

Authors:  M Somer; J Kallio; U Pesonen; K Pyykkö; R Huupponen; M Scheinin
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

6.  Determination of acetylator phenotype in Caucasians with caffeine.

Authors:  M Hildebrand; W Seifert
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Cognitive deterioration from long-term abuse of dextromethorphan: a case report.

Authors:  A Hinsberger; V Sharma; D Mazmanian
Journal:  J Psychiatry Neurosci       Date:  1994-11       Impact factor: 6.186

8.  Oxidative polymorphism of dextromethorphan in a Burundi population.

Authors:  F Nsabiyumva; Y Furet; E Autret; A P Jonville; M Breteau
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Dextromethorphan O-demethylation polymorphism in Jordanians.

Authors:  Y M Irshaid; H F al-Hadidi; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes.

Authors:  L B Anthony; T J Boeve; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.